2024-09-22 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

This report analyzes Eli Lilly and Co (LLY), a pharmaceutical company specializing in diabetes treatments, oncology, and neurology.

**1. Performance vs. S&P 500**

* **LLY's cumulative return:** 892.63%
* **S&P 500 (VOO) cumulative return:** 132.46%
* **Difference:** 760.17%
* **Relative divergence:** 94.27% (this means LLY's performance has been better than the S&P 500 for 94.27% of the time period considered).

**2. Recent Price Movement**

* **Closing price:** $921.49
* **5-day moving average:** $912.62
* **20-day moving average:** $928.87
* **60-day moving average:** $898.41

The 5-day moving average is below the closing price, indicating short-term upward momentum. The 20-day and 60-day moving averages are slightly above the closing price, suggesting potential for further upward movement.

**3. Technical Indicators**

* **RSI:** 37.22 
* **PPO:** -0.46
* **Delta_Previous_Relative_Divergence:** -5.73 (negative, suggesting short-term downward trend)
* **Expected_Return:** 46.29% (5-year expected return based on current investment)

The RSI suggests that LLY is currently in oversold territory, indicating potential for a rebound. The negative PPO and relative divergence indicate short-term downward pressure. However, the expected return remains positive, potentially suggesting long-term growth.

**4. Recent Earnings and Outlook**

| Date       | EPS     | Revenue          |
|------------|---------|-------------------|
| 2024-08-08 | 3.29    | $11.30 Billion   |
| 2024-04-30 | 2.49    | $8.77 Billion   |
| 2023-11-02 | -0.06   | $9.50 Billion   |
| 2023-08-08 | 1.96    | $8.31 Billion   |
| 2023-05-04 | 1.96    | $8.31 Billion   |

The most recent earnings (2024-08-08) beat analyst expectations, with EPS exceeding estimates by 0.06. Revenue also exceeded forecasts.  The trend suggests strong financial performance and continued growth.

**5. Summary**

* **Strong historical performance:** LLY has consistently outperformed the S&P 500.
* **Positive technical indicators:** The RSI suggests potential for a rebound, and expected return remains high. 
* **Strong financial performance:**  Recent earnings exceeded analyst expectations, indicating continued growth.

**6. Overall Analysis**

While short-term trends indicate some downward pressure, the strong historical performance, positive technical indicators, and solid financial performance of Eli Lilly and Co make it a potentially attractive investment. However, it is essential to consider individual investment goals and risk tolerance before making any investment decisions. 
